raises CHF 7.5M in seed financing round to advance precision cancer medicine through spatial single-cell proteomics
Summary
With this seed financing, we will boost our capacity to engage with clinical, biotech and pharma partners and accelerate the development of our first diagnostic product. Frank Laukien, CEO of Bruker Corporation and also co-chair of the AACR Cancer Evolution working group, commented: I believe that high-plex spatial single-cell proteomics has enormous potential for precision oncology, and for research towards a better functional understanding of the tumor microenvironment (TME). These novel precision medicine high-plex TME functional protein analysis strategies offer enormous opportunities for the future of onco-pathology and cancer tissue diagnostics.Dr. Florian Kainzinger, Managing Partner at Think.Health Ventures said Our team was impressed with the clinical impact the methods used by Navignostics were able to demonstrate at such an early stage in their company development. The company has a promising combination of team, technology and expertise and I am looking forward to complementing the Navignostics team with my experience in bringing diagnostic products to the market.Marie-Line Bachmann, Investment Manager Start-up Finance at ZKB, commented: Spatial single-cell proteomics have the potential to augment current genetics-based diagnostics by directly characterizing the proteins of the tumor and the surrounding cells.